相关实验视频

Updated: Jun 12, 2025

Bioluminescent Orthotopic Model of Pancreatic Cancer Progression

Bioluminescent Orthotopic Model of Pancreatic Cancer Progression

Published on: June 28, 2013

转移性胰腺癌与激活BRAFV600E突变:一个病例报告

Fang Li^1,2,3, Feng Shen^1,2,4

¹Department of Medical Oncology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen 361015, Fujian Province, China.

World journal of clinical cases

|June 9, 2025

概括

胰腺癌 (PC) 对标准治疗具有抗性. 分子分析在患者身上发现了BRAF突变,但向治疗的疗效有限,这强调了需要进一步研究的必要性.

科学领域:

在瘤学瘤学.
遗传学是一个遗传学.
内部医学内部医学

背景情况:

胰腺癌 (PC) 是一种高度恶性瘤,预后不佳.
标准治疗包括化疗,放射疗法和免疫疗法,其疗效有限.
报道了像BRAF V600E突变这样的基因组改变,但有针对性的治疗证据很少.

研究的目的:

为了呈现一个患有BRAF突变的胰腺癌病例.
评估PC中分子导向向治疗的临床有效性.
突出分子分析在PC管理中的重要性.

主要方法:

据报道,一名33岁的男性患有晚期胰腺癌的病例.
患者接受了标准化疗 (gemcitabine和nab-paclitaxel),疾病进展.
分子测试显示了BRAF突变,随后进行了向治疗 (达布拉费尼布/特拉美替尼布).

主要成果:

患者在标准化疗中经历了疾病进展.
用达布拉费尼布/特拉美丁尼布进行的向治疗显示,瘤标志物 (CA19-9,CEA) 的降低.
尽管最初有反应,但该患者在两个月的向治疗后最终屈服于疾病.

结论:

在胰腺癌中,BRAF的变化并不常见.
这一案例凸显了分子分析对于识别PC中可操作的突变的重要性.
向治疗可能会提供暂时的好处,但在管理高瘤负担的高级PC方面仍然存在挑战.

关键词:

在BRAF基因突变中.案例报告案例报告胰腺癌是一种癌症.预后预后预测预测有针对性的治疗.

更多相关视频

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

A Preclinical Murine Model of Hepatic Metastases

A Preclinical Murine Model of Hepatic Metastases

Published on: September 27, 2014

相关概念视频

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...